Singapore - inglese - HSA (Health Sciences Authority)

zyfas pharma pte ltd - azacitidine - injection, powder, lyophilized, for suspension - azacitidine 100 mg/ml

Singapore - inglese - HSA (Health Sciences Authority)

natco pharma asia pte. ltd. - azacitidine - injection - azacitidine 100mg

Unione Europea - inglese - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 % to 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 % to 30 % blasts and multi-lineage dysplasia, according to world health organization (who) classification,aml with > 30 % marrow blasts according to the who classification.

Unione Europea - inglese - EMA (European Medicines Agency)

mylan ireland limited - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Unione Europea - inglese - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidine - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastic agents - azacitidine accord is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:- intermediate-2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),- chronic myelomonocytic leukaemia (cmml) with 10-29 % marrow blasts without myeloproliferative disorder,- acute myeloid leukaemia (aml) with 20-30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,- aml with >30% marrow blasts according to the who classification.

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - azacitidine 100 mg - powder for suspension for injection - 25 mg/ml - azacitidine 100 mg/ml - azacitidine

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - azacitidine 100 mg - powder for suspension for injection - 25 mg/ml - azacitidine 100 mg - azacitidine

Canada - inglese - Health Canada

jamp pharma corporation - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents

Canada - inglese - Health Canada

fresenius kabi canada ltd - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents

Canada - inglese - Health Canada

hikma canada limited - azacitidine - powder for suspension - 100mg - azacitidine 100mg - antineoplastic agents